Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Regulatory News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.19
Bid: 0.18
Ask: 0.20
Change: 0.00 (0.00%)
Spread: 0.02 (11.111%)
Open: 0.19
High: 0.00
Low: 0.00
Prev. Close: 0.19
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

7 Apr 2022 15:44

RNS Number : 6981H
Nuformix PLC
07 April 2022
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BYW79Y38

Issuer Name

NUFORMIX PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An event changing the breakdown of voting

3. Details of person subject to the notification obligation

Name

CPI Enterprises Limited

City of registered office (if applicable)

Redcar

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

04-Apr-2022

6. Date on which Issuer notified

07-Apr-2022

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

3.750000

0.000000

3.750000

26600000

Position of previous notification (if applicable)

4.320000

0.000000

4.320000

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BYW79Y38

26600000

 

3.750000

 

Sub Total 8.A

26600000

3.750000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

 

 

 

 

Sub Total 8.B1

 

 

 

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

 

 

 

 

 

Sub Total 8.B2

 

 

 

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

 

 

 

 

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

07-Apr-2022

13. Place Of Completion

Wilton, Redcar, UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLSSUFLWEESEDL
Date   Source Headline
15th Jan 202012:43 pmRNSAmendment to Notice
10th Jan 202011:45 amRNSIssue of Equity
8th Jan 20208:17 amRNSHolding(s) in Company
24th Dec 20197:00 amRNSHalf-year Report
25th Nov 20194:41 pmRNSSecond Price Monitoring Extn
25th Nov 20194:36 pmRNSPrice Monitoring Extension
25th Nov 20197:00 amRNSUpdate and Placing Announcement
28th Oct 20192:05 pmRNSSecond Price Monitoring Extn
28th Oct 20192:00 pmRNSPrice Monitoring Extension
28th Oct 20198:30 amRNSIssue of Equity
25th Oct 201911:11 amRNSStatement re. Share Price Movement
25th Oct 20199:05 amRNSSecond Price Monitoring Extn
25th Oct 20199:00 amRNSPrice Monitoring Extension
20th Sep 20192:05 pmRNSSecond Price Monitoring Extn
20th Sep 20192:00 pmRNSPrice Monitoring Extension
10th Sep 20194:49 pmRNSAGM Results
10th Sep 20197:00 amRNSDirectorate Change
9th Sep 20197:00 amRNSEbers Cannabinoid Collaboration Update
6th Sep 20197:30 amRNSAppointment of Dr Muhunthan Thillai
4th Sep 20197:30 amRNSHolding(s) in Company
1st Aug 20199:30 amRNSAnnual Financial Report
29th Jul 20197:00 amRNSHolding(s) in Company
18th Jul 20197:00 amRNSFinal Results
7th Jun 20197:00 amRNSHolding(s) in Company
6th Jun 20197:00 amRNSHolding(s) in Company
30th May 201911:05 amRNSSecond Price Monitoring Extn
30th May 201911:00 amRNSPrice Monitoring Extension
30th May 20197:01 amRNSPositive Results for NXP001 Clinical Trial
28th May 20197:00 amRNSHolding(s) in Company - Amendment
24th May 20197:30 amRNSHolding(s) in Company
24th May 20197:00 amRNSLoan Conversion
22nd May 20197:00 amRNSHolding(s) in Company
22nd May 20197:00 amRNSHolding(s) in Company
22nd May 20197:00 amRNSHolding(s) in Company
15th May 20194:40 pmRNSSecond Price Monitoring Extn
15th May 20194:35 pmRNSPrice Monitoring Extension
15th May 20197:00 amRNSNuformix Achieves 2nd NXP001 Development Milestone
10th May 20199:00 amRNSPrice Monitoring Extension
8th May 20197:30 amRNSHolding(s) in Company
9th Apr 20197:00 amRNSStrategic Cannabinoid Agreement
5th Apr 20197:00 amRNSNotification Major Share Interests
22nd Mar 20197:00 amRNSNuformix Commences NXP001 Clinical Trial
27th Feb 20197:00 amRNSMHRA approval for NXP001
20th Feb 20196:16 pmRNSHolding(s) in Company
20th Dec 20187:00 amRNSUnaudited Half Year Results
3rd Dec 20187:00 amRNSReports Results from Novel IPF Pre-Clinical Trial
27th Nov 20187:00 amRNSExpansion of NXP001 Agreement & Milestone Payment
28th Sep 201810:09 amRNSDirector/PDMR Shareholding
28th Sep 20187:00 amRNSAdditional New NXP002 Patent Filing
19th Sep 20182:33 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.